<DOC>
	<DOCNO>NCT00017433</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness arsenic trioxide treat patient relapsed refractory stage II stage III multiple myeloma .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient relapse refractory stage II III multiple myeloma treat arsenic trioxide . II . Determine overall relapse-free survival rate patient treated drug . III . Determine safety profile drug patient . OUTLINE : Patients receive arsenic trioxide IV day 1-5 8-12 . Treatment repeat every 4 week 6 course . Patients follow 4 week last treatment dose . PROJECTED ACCRUAL : A total 55 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Stage II III ( DurieSalmon ) Relapsed refractory conventional therapy No monoclonal gammopathy indolent smolder myeloma Measurable disease serum urine M protein and/or plasmacytoma PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 70100 % Life expectancy : 3 month Hematopoietic : Granulocyte count great 1,200/mm3 Platelet count great 100,000/mm3 Hemoglobin great 10 g/dL Hepatic : Bilirubin le 2 time upper limit normal ( ULN ) SGOT/SGPT le 2 time ULN Renal : Creatinine great 2.5 mg/dL Cardiovascular : Absolute QT interval le 460 msec presence normal potassium magnesium level PRIOR CONCURRENT THERAPY : Biologic therapy : At least 28 day since prior biologic therapy Chemotherapy : No 3 prior chemotherapy regimen , include 2 cytotoxic regimen AND 1 highdose cytotoxic regimen part stem cell transplantation Endocrine therapy : At least 28 day since prior endocrine therapy Radiotherapy : At least 28 day since prior radiotherapy ( except focal radiotherapy symptom control ) Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>